Topic
peptides
FDA Panel Endorses Unproven Peptides, Opening Door for Compounding Pharmacy Manufacturing
An FDA advisory panel voted 8-6 to recommend reclassifying three unproven peptides—BPC-157, KPV, and TB-500—allowing compounding pharmacies to produce them. A fourth peptide, MOTs-C, received a 7-5 vote in favor. The decision could reshape pharmaceutical manufacturing supply chains, as China and India are major suppliers of these peptides.
Peptide Manufacturing Capacity Investments Surge Ahead of FDA Reclassification Decision
Telehealth companies and compounding pharmacies are investing in peptide manufacturing capacity ahead of a pivotal FDA reclassification meeting on July 23-24. Hims & Hers Health purchased a peptide manufacturing facility in February 2025, while Olympia Pharmaceuticals has spent heavily on formula development. Testing investments exceed $100,000 per product.
Scientists Use AI and Quantum Computing to Generate New Peptides in Spare Time
Researchers at the Technical University of Denmark used a hybrid AI-quantum computing system to generate novel peptides, achieving better results than classical models especially with limited data. The work, done on weekends with leftover funds, could accelerate personalized immunotherapies and vaccines.